FDA
-
-
-
-
-
-
-
William Blair on ARS Pharmaceuticals Inc (SPRY): FDA label update 'viewed positively'
-
-
-
-
-
-
-
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
-
-
-
-
-
-
-
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
-
-
-
-
-
-
-
ARS Pharmaceuticals gains Japan approval for needle-free epinephrine spray
-
-
-
-
-
-
-
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilo
-
-
-
-
-
-
-
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
-
-
-
-
-
-
-
ARS Pharmaceuticals (SPRY) Announces Filings for Approval of neffy in China, Japan and Australia
-
324,165 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

